241 related articles for article (PubMed ID: 22398037)
61. A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.
Luo YY; Tao Y; Cai XF; Zhang WL; Long QX; Guo H; Huang AL; Hu JL
Antiviral Res; 2016 Feb; 126():99-107. PubMed ID: 26738784
[TBL] [Abstract][Full Text] [Related]
62. Antiviral resistance mutations potentiate hepatitis B virus immune evasion through disruption of its surface antigen a determinant.
Sloan RD; Ijaz S; Moore PL; Harrison TJ; Teo CG; Tedder RS
Antivir Ther; 2008; 13(3):439-47. PubMed ID: 18572757
[TBL] [Abstract][Full Text] [Related]
63. Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the "fingers" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene.
Torresi J; Earnest-Silveira L; Civitico G; Walters TE; Lewin SR; Fyfe J; Locarnini SA; Manns M; Trautwein C; Bock TC
Virology; 2002 Jul; 299(1):88-99. PubMed ID: 12167344
[TBL] [Abstract][Full Text] [Related]
64. Sequence analysis of the polymerase gene in hepatitis B virus infected blood donors in Iran.
Sharifi Z; Yari F; Gharebaghiyan A
Arch Iran Med; 2012 Feb; 15(2):88-90. PubMed ID: 22292578
[TBL] [Abstract][Full Text] [Related]
65. Amino acid polymorphism in the reverse transcriptase region of hepatitis B virus and the relationship with nucleos(t)ide analogues treatment for preventing mother-to-infant transmission.
Chen J; Yan L; Zhu FC; Liu JX; Li RC; Wang FZ; Li J; Zhuang H
J Med Virol; 2014 Aug; 86(8):1288-95. PubMed ID: 24777553
[TBL] [Abstract][Full Text] [Related]
66. Mutation analysis of hepatitis B virus reverse transcriptase region among untreated chronically infected patients in Ahvaz city (South-West of Iran).
Hamidi-Fard M; Makvandi M; Samarbaf-Zadeh A; Hajiani E; Shayesteh A; Masjedizadeh A
Indian J Med Microbiol; 2013; 31(4):360-5. PubMed ID: 24064642
[TBL] [Abstract][Full Text] [Related]
67. Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy.
Chen L; Zhang Q; Yu DM; Wan MB; Zhang XX
J Hepatol; 2009 May; 50(5):895-905. PubMed ID: 19304333
[TBL] [Abstract][Full Text] [Related]
68. In vitro study of the effects of precore and lamivudine-resistant mutations on hepatitis B virus replication.
Heipertz RA; Miller TG; Kelley CM; Delaney WE; Locarnini SA; Isom HC
J Virol; 2007 Apr; 81(7):3068-76. PubMed ID: 17215289
[TBL] [Abstract][Full Text] [Related]
69. Substitutions of rtL228 and/or L229 are involved in the regulation of replication and HBsAg secretion in hepatitis B virus, and do not affect susceptibility to nucleos(t)ide analogs.
Qin B; Zhou Y; Zhou G; Xu X; Wang Y; Chen J
Mol Med Rep; 2017 Dec; 16(6):9678-9684. PubMed ID: 29039614
[TBL] [Abstract][Full Text] [Related]
70. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations.
Choe WH; Kim K; Lee SY; Choi YM; Kwon SY; Kim JH; Kim BJ
World J Gastroenterol; 2019 Sep; 25(33):4985-4998. PubMed ID: 31543688
[TBL] [Abstract][Full Text] [Related]
71. Different Variants in Reverse Transcriptase Domain Determined by Ultra-deep Sequencing in Treatment-naïve and Treated Indonesian Patients Infected with Hepatitis B Virus.
Wasityastuti W; Yano Y; Widasari DI; Yamani LN; Ratnasari N; Heriyanto DS; Okada R; Tanahashi T; Murakami Y; Azuma T; Hayashi Y
Kobe J Med Sci; 2016 Jun; 62(1):E1-8. PubMed ID: 27492206
[TBL] [Abstract][Full Text] [Related]
72. Differential impact of immune escape mutations G145R and P120T on the replication of lamivudine-resistant hepatitis B virus e antigen-positive and -negative strains.
Amini-Bavil-Olyaee S; Vucur M; Luedde T; Trautwein C; Tacke F
J Virol; 2010 Jan; 84(2):1026-33. PubMed ID: 19889778
[TBL] [Abstract][Full Text] [Related]
73. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine.
Tenney DJ; Levine SM; Rose RE; Walsh AW; Weinheimer SP; Discotto L; Plym M; Pokornowski K; Yu CF; Angus P; Ayres A; Bartholomeusz A; Sievert W; Thompson G; Warner N; Locarnini S; Colonno RJ
Antimicrob Agents Chemother; 2004 Sep; 48(9):3498-507. PubMed ID: 15328117
[TBL] [Abstract][Full Text] [Related]
74. [Low prevalence of hepatitis B virus primary drug resistance in Southern Spain].
Alvarez Estévez M; Chueca-Porcuna N; Guillot-Suay V; Peña-Monje A; García-García F; García-García F
Enferm Infecc Microbiol Clin; 2013 Oct; 31(8):520-2. PubMed ID: 23602529
[TBL] [Abstract][Full Text] [Related]
75. Telbivudine, a nucleoside analog inhibitor of HBV polymerase, has a different in vitro cross-resistance profile than the nucleotide analog inhibitors adefovir and tenofovir.
Seifer M; Patty A; Serra I; Li B; Standring DN
Antiviral Res; 2009 Feb; 81(2):147-55. PubMed ID: 19028525
[TBL] [Abstract][Full Text] [Related]
76. In vitro activity of cepharanthine hydrochloride against clinical wild-type and lamivudine-resistant hepatitis B virus isolates.
Zhou YB; Wang YF; Zhang Y; Zheng LY; Yang XA; Wang N; Jiang JH; Ma F; Yin DT; Sun CY; Wang QD
Eur J Pharmacol; 2012 May; 683(1-3):10-5. PubMed ID: 22387093
[TBL] [Abstract][Full Text] [Related]
77. High incidence of treatment-induced and vaccine-escape hepatitis B virus mutants among human immunodeficiency virus/hepatitis B-infected patients.
Lacombe K; Boyd A; Lavocat F; Pichoud C; Gozlan J; Miailhes P; Lascoux-Combe C; Vernet G; Girard PM; Zoulim F
Hepatology; 2013 Sep; 58(3):912-22. PubMed ID: 23468093
[TBL] [Abstract][Full Text] [Related]
78. Convergence and coevolution of hepatitis B virus drug resistance.
Thai H; Campo DS; Lara J; Dimitrova Z; Ramachandran S; Xia G; Ganova-Raeva L; Teo CG; Lok A; Khudyakov Y
Nat Commun; 2012 Apr; 3():789. PubMed ID: 22510694
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of the
Arikan A; Sayan M; Sanlidag T; Suer K; Akcali S; Guvenir M
Pol J Microbiol; 2019 Sep; 68(3):317-322. PubMed ID: 31880877
[TBL] [Abstract][Full Text] [Related]
80. The amino acid substitutions rtP177G and rtF249A in the reverse transcriptase domain of hepatitis B virus polymerase reduce the susceptibility to tenofovir.
Qin B; Budeus B; Cao L; Wu C; Wang Y; Zhang X; Rayner S; Hoffmann D; Lu M; Chen X
Antiviral Res; 2013 Feb; 97(2):93-100. PubMed ID: 23261845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
